首页 正文

Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer

{{output}}
Background: PARP inhibitors have shown limited efficacy in pancreatic cancer, partly due to the low prevalence of BRCA mutations, which restricts their clinical use. Because DNA damage checkpoint kinases play critical roles in ma... ...